Malmö, May 23, 2018
Acarix AB recruits Per Persson as Chief Commercial Officer
Acarix AB (publ) (“Acarix”), today announced the recruitment of Per Persson as new Chief Commercial Officer to accelerate the sales execution for the CADScor®System for Coronary Artery Disease (CAD) risk assessment. He has a solid background in sales and marketing of medical technology products in general and in cardiology in particular.
“The Acarix CADScor®System is already in use in several clinics, and our priority is now to accelerate sales of the system primarily in Germany and the Nordic markets. Per Persson’s vast experience from similar positions in other, global medtech companies, will be invaluable for the strengthening of our commercial organization”, said Christian Lindholm, Acarix’s interim Chief Executive Officer.
Per Persson comments: “I am passionate about the implementation of improved methodologies and the Acarix CADScor®System is a prime example of this; adding significant benefits to the patient and the entire healthcare system. I very much look forward to joining the team at Acarix and the opportunities that comes with my new assignment.”
Per Persson has more than 25 years of experience from executive management, sales and marketing positions in global medtech companies. He joins Acarix from Airsonett AB where he held the position as CEO combined with the role of VP Sales and Marketing. Prior to Airsonett, Per held the position as VP Sales at Atos Medical, Senior Director Marketing at St. Jude Medical and as a Director Nordic Region at Boston Scientific.
Per Persson will join Acarix in August, 2018.
Contact:
Christian Lindholm, interim Chief Executive Officer, E-mail: secli@acarix.com, Phone: +46 705 118 333
Notes to editors:
Acarix was established in 2009, and since 2010 investors Sunstone Life Science Ventures (DK) and SEED Capital (DK) have supported it towards market introduction. Acarix was listed on Nasdaq First North Premier in 2016 and has attracted a highly-experienced management team.
The Acarix CADScor®System combines ultra-sensitive acoustic detection of turbulent arterial flow and myocardial movement with advanced algorithms in a portable device to provide a patient-specific score to non-invasively assess the risk for Coronary Artery Disease (CAD) in less than 10 minutes. The system has been clinically validated.
See more at www.acarix.com. Press kit: http://www.acarix.com/about-us/press-downloads/.
